

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

NCI-H838

RRID:CVCL_1594

Type: Cell Line

Proper Citation

RRID:CVCL_1594

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1594

Proper Citation: RRID:CVCL_1594

Description: Cell line NCI-H838 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:8806092](#), [PMID:11030152](#), [PMID:18083107](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:25714623](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Karyotypic information: Has lost chromosome Y (PubMed=25714623)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H838

Synonyms: H838, H-838, NCIH838

Cross References: BTO:BTO_0003239, CLO:CLO_0008121, EFO:EFO_0002307, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5844, BioGRID_ORCS_Cell_line:517, BioSample:SAMN03471317, BioSample:SAMN10987750, cancercellines:CVCL_1594,

CCRID:3101HUMSCSP588, Cell_Model_Passport:SIDM01150, ChEMBL-Cells:ChEMBL3308122, ChEMBL-Targets:ChEMBL1075547, CLS:305097, Cosmic:687830, Cosmic:877239, Cosmic:877414, Cosmic:903580, Cosmic:910399, Cosmic:980968, Cosmic:1032440, Cosmic:1802315, Cosmic:1870278, Cosmic:2042864, Cosmic:2630411, Cosmic-CLP:910399, DepMap:ACH-000416, EGA:EGAS00001000978, GDSC:910399, GEO:GSM206500, GEO:GSM274794, GEO:GSM274822, GEO:GSM513966, GEO:GSM514352, GEO:GSM784196, GEO:GSM794302, GEO:GSM827482, GEO:GSM887448, GEO:GSM888528, GEO:GSM1374765, GEO:GSM1374766, GEO:GSM1670268, IARC_TP53:25039, IARC_TP53:30215, IGRhCellID:NCIH838, KCB:KCB 2021016YJ, LiGeA:CCLE_510, LINCS_LDP:LCL-1623, NCI-DTP:NCI-H838, PharmacODB:NCIH838_1142_2019, PRIDE:PXD030304, Progenetix:CVCL_1594, PubChem_Cell_line:CVCL_1594, Wikidata:Q54908128

ID: CVCL_1594

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260913T004957+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H838.

No alerts have been found for NCI-H838.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Scholler J, et al. (2026) Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer. *Frontiers in immunology*, 17, 1805950.

Mi W, et al. (2026) LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer. *Cell reports*, 45(6), 117487.

Fu R, et al. (2026) Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. *bioRxiv : the preprint server for biology*.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Scholler J, et al. (2025) Engineering a Juxtamembrane-Targeting CAR T-Cell Against Mesothelin: A Novel Binder Resilient to Shed Antigen in Ovarian and Pancreatic Cancer. *bioRxiv : the preprint server for biology*.

Park J, et al. (2025) MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer. *Cell reports*, 44(6), 115722.

Kotagiri S, et al. (2024) Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer. *Cell chemical biology*, 31(12), 2069.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. *Cancer immunology research*, 12(4), 491.

Mao C, et al. (2024) Unraveling ETC complex I function in ferroptosis reveals a potential ferroptosis-inducing therapeutic strategy for LKB1-deficient cancers. *Molecular cell*, 84(10), 1964.

Sun F, et al. (2024) Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. *eLife*, 12.

Suvilesh KN, et al. (2024) Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(17), 3855.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Aboukassim T, et al. (2023) A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants. *Cell reports*, 42(9), 113104.

Tsai JW, et al. (2022) FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits. *Cancer research*, 82(17), 2980.

Spears ME, et al. (2022) De novo sphingolipid biosynthesis necessitates detoxification in cancer cells. *Cell reports*, 40(13), 111415.

Luo X, et al. (2022) Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases. *iScience*, 25(3), 103985.

Su H, et al. (2021) Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis. *Cancer cell*, 39(5), 678.

Ippolito MR, et al. (2021) Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. *Developmental cell*, 56(17), 2440.

Hadi K, et al. (2020) Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. *Cell*, 183(1), 197.

Chen X, et al. (2020) Identification and Target-Modification of SL-BBI: A Novel Bowman-Birk Type Trypsin Inhibitor from *Sylvirana latouchii*. *Biomolecules*, 10(9).